Skip to main content

Table 1 Profile of major fatty acids, at baseline and with rosiglitazone

From: Peroxisome proliferator-activated receptor gamma modulation and lipogenic response in adipocytes of small-for-gestational age offspring

Fatty Acids Percent of Total (%)

Ā 

Control

SGA

Fatty Acid

Baseline

Rosiglitazone

Baseline

Rosiglitazone

Palmitate 16:0

36.4ā€‰Ā±ā€‰1.5

37.9ā€‰Ā±ā€‰1.1

37.5ā€‰Ā±ā€‰0.7

37.7ā€‰Ā±ā€‰2.4

Palmitoleate 16:1n-7

3.4ā€‰Ā±ā€‰0.1

3.09ā€‰Ā±ā€‰0.04

3.4ā€‰Ā±ā€‰0.1

3.3ā€‰Ā±ā€‰0.3

Stearate 18:0

22.6ā€‰Ā±ā€‰0.9

29.1ā€‰Ā±ā€‰0.9*

20.8ā€‰Ā±ā€‰0.6

22.4ā€‰Ā±ā€‰1.4c

Oleate 18:1n-9

19.7ā€‰Ā±ā€‰0.7

17.4ā€‰Ā±ā€‰0.4

20.0ā€‰Ā±ā€‰0.3

20.1ā€‰Ā±ā€‰1.2

Vaccenate 18:1n-7

12.0ā€‰Ā±ā€‰0.5

10.4ā€‰Ā±ā€‰0.2

13.2ā€‰Ā±ā€‰0.3

12.1ā€‰Ā±ā€‰0.9

  1. Cpā€‰<ā€‰0.05 compared with Control receiving the same treatment.
  2. *pā€‰<ā€‰0.05 compared to the untreated state within the same group.
  3. The fatty acid percentages of total are presented as the meanā€‰Ā±ā€‰the standard error of the mean (SEM). With rosiglitazone treatment, Controls demonstrated increased stearate abundance.